Sean Laaman Analyst PerformanceAnalyst at Morgan StanleySean Laaman is a stock analyst at Morgan Stanley in the healthcare sector, covering 14 publicly traded companies. Over the past year, Sean Laaman has issued 39 stock ratings, including buy, hold, and sell recommendations. While full access to Sean Laaman's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Sean Laaman's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings47 Last 6 YearsBuy Recommendations67.44% 29 Buy RatingsCompanies Covered14 Unique Companies Ratings Distribution43RatingsDistribution of strong buy, buy, hold, and sell ratings by Sean Laaman.RatingPercentageCount Strong Buy0.0%0 ratings Buy67.4%29 ratings Hold27.9%12 ratings Sell4.7%2 ratingsOut of 43 total stock ratings issued by Sean Laaman at Morgan Stanley, the majority (67.4%) have been Buy recommendations, followed by 27.9% Hold and 4.7% Sell.Best & Worst CallsBest Call0000.0%AXSMJul 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%RMDJun 2020Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ92.9% of companies on NASDAQ13 companiesNYSE7.1% of companies on NYSE1 companySean Laaman, an analyst at Morgan Stanley, currently covers 14 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare14 companies100.0%Sean Laaman of Morgan Stanley specializes in stock coverage within the Healthcare sector.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY10 companies71.4%PHARMACEUTICALS2 companies14.3%HEALTHCARE TECHNOLOGY1 company7.1%HEALTHCARE EQUIPMENT & SUPPLIES1 company7.1% Sean Laaman's Ratings History at Morgan Stanley Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsMPLTMaplight Therapeutics7/28/2026Reiterated Rating$9.90$21.00Equal Weight$0.0000.00% ROIEXELExelixis7/23/2026Boost Price Target$55.68$53.00Equal Weight$0.0000.00% ROIERASErasca7/20/2026Boost Price Target$19.17$21.00Equal Weight$0.0000.00% ROIEXELExelixis6/22/2026Reiterated Rating$51.35Positive$0.0000.00% ROIIRONDisc Medicine6/15/2026Boost Price Target$70.09$85.00Overweight$0.0000.00% ROIAXSMAxsome Therapeutics6/11/2026Upgrade$246.34Overweight$0.0000.00% ROIBBIOBridgeBio Pharma5/28/2026Boost Price Target$65.98$98.00Overweight$0.0000.00% ROIGENBGenerate Biomedicines5/14/2026Boost Price Target$15.88$22.00Overweight$0.0000.00% ROIIRONDisc Medicine5/14/2026Boost Price Target$69.30$80.00Overweight$0.0000.00% ROICERTCertara5/12/2026Lower Price Target$5.13$10.00Equal Weight$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. EXELExelixis5/6/2026Boost Price Target$48.45$50.00Equal Weight$0.0000.00% ROIAXSMAxsome Therapeutics5/5/2026Boost Price Target$227.99$242.00Equal Weight$0.0000.00% ROIGENBGenerate Biomedicines3/24/2026Initiated Coverage$12.52$20.00Overweight$0.0000.00% ROIEIKNEikon Therapeutics3/2/2026Initiated Coverage$13.78$32.00Overweight$0.0000.00% ROIBBIOBridgeBio Pharma2/25/2026Boost Price Target$66.71$98.00Overweight$0.0000.00% ROIAXSMAxsome Therapeutics2/24/2026Set Price Target$170.97$207.00$0.0000.00% ROIIRONDisc Medicine2/17/2026Set Price Target$60.55$75.00$0.0000.00% ROIEXELExelixis2/2/2026Boost Price Target$41.23$49.00Equal Weight$0.0000.00% ROIERASErasca1/26/2026Set Price Target$9.96$10.00$0.0000.00% ROICGONCG Oncology1/9/2026Set Price Target$54.23$93.00$0.0000.00% ROIONCBeOne Medicines1/8/2026Reiterated Rating$333.87$405.00Overweight$0.0000.00% ROIIRONDisc Medicine1/8/2026Reiterated Rating$80.94$120.00Overweight$0.0000.00% ROIAXSMAxsome Therapeutics1/8/2026Downgrade$170.69Reduce$0.0000.00% ROIAXSMAxsome Therapeutics1/8/2026Reiterated Rating$170.69$204.00Equal Weight$0.0000.00% ROIEXELExelixis1/8/2026Reiterated Rating$46.19$48.00Equal Weight$0.0000.00% ROIBBIOBridgeBio Pharma1/6/2026Initiated Coverage$73.42$96.00Overweight$0.0000.00% ROIAXSMAxsome Therapeutics12/31/2025Reiterated Rating$183.22Overweight$0.0000.00% ROICERTCertara12/18/2025Lower Price Target$9.10$12.00Equal Weight$0.0000.00% ROIMPLTMaplight Therapeutics11/21/2025Initiated Coverage$13.29$34.00Overweight$0.0000.00% ROIEXELExelixis11/5/2025Boost Price Target$40.36$45.00Overweight$0.0000.00% ROIAXSMAxsome Therapeutics11/4/2025Boost Price Target$133.96$196.00Overweight$0.0000.00% ROIIRONDisc Medicine10/30/2025Boost Price Target$85.75$115.00Overweight$0.0000.00% ROIZBIOZenas BioPharma10/27/2025Boost Price Target$31.98$34.00Overweight$0.0000.00% ROIEXELExelixis10/21/2025Lower Price Target$35.32$44.00Overweight$0.0000.00% ROIRMDResMed10/21/2025Boost Price Target$271.44$304.00Overweight$0.0000.00% ROIONCBeOne Medicines10/20/2025Boost Price Target$318.05$383.00Overweight$0.0000.00% ROIAXSMAxsome Therapeutics10/20/2025Boost Price Target$127.94$194.00Overweight$0.0000.00% ROIEXELExelixis9/17/2025Boost Price Target$40.54$50.00Overweight$0.0000.00% ROIIRONDisc Medicine8/18/2025Boost Price Target$60.07$90.00Overweight$0.0000.00% ROIEXELExelixis7/29/2025Lower Price Target$37.20$46.00Overweight$00.0000.00% ROIIt’s not about Greenland (Ad)The petrodollar arrangement that anchored the US dollar for 50 years quietly expired in June 2024. Since then, China has cut its Treasury holdings by 45% from their peak, and BRICS nations offloaded $47 billion of American debt in a single month. The Trump administration has responded with a $12 billion critical minerals stockpile called Project Vault, equity stakes in miners like MP Materials and Lithium Americas, and a push to secure resources from Greenland to Ukraine. Porter Stansberry lays out the full story in a new documentary, including five companies positioned at the chokepoints of what he calls Trump's New Dollar.Watch the full documentary before December's economic summit in MiamiIRONDisc Medicine7/3/2025Initiated Coverage$53.17$85.00Overweight$00.0000.00% ROICERTCertara7/3/2025Initiated Coverage$11.49$16.00Equal Weight$0.0000.00% ROIAXSMAxsome Therapeutics7/3/2025Initiated Coverage$103.91$190.00Overweight$000.0000.00% ROIONCBeOne Medicines6/27/2025Boost Price Target$244.34$330.00Overweight$000.0000.00% ROIALECAlector3/7/2025Reiterated Rating$1.48$1.50Underweight$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenBarclaysRoyal Bank Of CanadaMorgan StanleyJefferies Financial GroupThe Goldman Sachs GroupBMO Capital MarketsSanford C. BernsteinBerenberg BankBNP Paribas ExaneCompass PointPiper SandlerCanadian Imperial Bank of CommerceWeiss RatingsUBS Group Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
